Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60

Bertrand Tombal; Yohann Loriot

doi:10.1016/j.euo.2025.01.010

Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60

Bertrand Tombal, Yohann Loriot

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

langue originale	Anglais
Pages (de - à)	853
Nombre de pages	1
journal	European urology oncology
Volume	8
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.euo.2025.01.010
état	Publié - 1 juin 2025

Accès au document

10.1016/j.euo.2025.01.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Tombal, B., & Loriot, Y. (2025). Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60. European urology oncology, 8(3), 853. https://doi.org/10.1016/j.euo.2025.01.010

Tombal, Bertrand ; Loriot, Yohann. / Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re : Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60. Dans: European urology oncology. 2025 ; Vol 8, Numéro 3. p. 853.

@article{8435246ac84d4171a0ac539168d990c9,

title = "Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60",

author = "Bertrand Tombal and Yohann Loriot",

year = "2025",

month = jun,

day = "1",

doi = "10.1016/j.euo.2025.01.010",

language = "English",

volume = "8",

pages = "853",

journal = "European urology oncology",

issn = "2588-9311",

number = "3",

}

Tombal, B & Loriot, Y 2025, 'Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60', European urology oncology, VOL. 8, Numéro 3, p. 853. https://doi.org/10.1016/j.euo.2025.01.010

Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60. / Tombal, Bertrand; Loriot, Yohann.
Dans: European urology oncology, Vol 8, Numéro 3, 01.06.2025, p. 853.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re

T2 - Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60

AU - Tombal, Bertrand

AU - Loriot, Yohann

PY - 2025/6/1

Y1 - 2025/6/1

UR - http://www.scopus.com/inward/record.url?scp=105008103725&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2025.01.010

DO - 10.1016/j.euo.2025.01.010

M3 - Letter

C2 - 39915217

AN - SCOPUS:105008103725

SN - 2588-9311

VL - 8

SP - 853

JO - European urology oncology

JF - European urology oncology

IS - 3

ER -

Tombal B, Loriot Y. Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60. European urology oncology. 2025 juin 1;8(3):853. doi: 10.1016/j.euo.2025.01.010